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Background/Aims: To investigate pre-existing hepatitis B 
virus (HBV) quasispecies and the genotypic evolution of sev-
eral variants. Methods: From six patients with lamivudine 
(LAM) failure, serum samples at pretreatment, 6 months 
of LAM therapy, and virologic breakthrough were obtained. 
One hundred clones with HBV inserts in each patient were 
sequenced at each time point. Pretreatment serum samples 
were also analyzed from six patients who achieved good 
responses to LAM therapy. Results: Among the six patients 
with LAM failure, the analysis of 100 clones from patient 1 
revealed the substitutions L180M in 1% of clones and V173L 
in 2% of clones. Patient 2 had substitutions of L80V, W153Q, 
and L180M. In patient 3, mutations conferring resistance 
to adefovir at V84I (5%), I169L (1%), and N236H (7%) and 
entecavir at S202G (2%) were detected. Patient 4 had muta-
tions at T128N (1%), I169L (1%), V173L (2%), A181V (1%), 
and Q215H (1%). In patient 5, M204V/I was detected in 1% 
and 2% of clones, respectively. L80I and V173L were also 
identified in patient 6. In the six patients who responded to 
LAM, the degree of overall quasispecies was less than those 
with LAM failure. Conclusions: Various HBV quasispecies as-
sociated with drug resistance existed before treatment, and 
the quasispecies dynamically changed through LAM therapy. 
(Gut	Liver	2013;7:329-334)
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INTRODUCTION
Hepatitis B virus (HBV) is an enveloped DNA virus and rep-
licates via reverse transcription of the genomic RNA template. 
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This process includes polymerization of the minus-strand DNA, 
degradation of the RNA intermediate and incomplete synthesis 
of the plus-strand.1 However, HBV reverse transcriptase (RT) is 
an error-prone enzyme that lacks 3’-5’ proofreading capacity.2 
Hence, it is responsible for many nucleotide substitutions during 
replication of approximate 1011 molecules/day.
Lamivudine (LAM), the first approved oral nucleoside ana-
logue, has an excellent safety profile and is effective in inducing 
viral suppression, hepatitis B e antigen (HBeAg) seroconversion, 
and decreasing the progression of liver fibrosis.3,4 However, it is 
associated with high rates of viral resistance; the prevalence of 
genotypic resistance after 8 years was 76%.5 The main muta-
tion associated with LAM resistance is rtM204I/V. The rtL180M 
mutation is the most common compensatory mutation, contrib-
uting to increasing either replication efficiency and/or antiviral 
resistance.6 With various patterns of mutations leading to LAM 
resistance, the initial benefits provided by LAM are reduced dur-
ing long-term follow-up.7 Accordingly, LAM is no longer rec-
ommended as a first-line agent for naïve patients with chronic 
hepatitis B (CHB).8
Entecavir (ETV), a carboxylic analogue of guanosine, was su-
perior to LAM in HBV DNA reduction and in inducing histolog-
ic improvement in phase III trials for both HBeAg-positive and 
HBeAg-negative CHB.9-11 Resistance to ETV in treatment-naïve 
patients is known to be rare, occurring in 1.1% of patients after 
4 years of therapy, and is associated with two different muta-
tion profiles.12 Interestingly, resistance to ETV includes LAM 
resistance mutations, rtM250V±rtI169T+rtM204V+rtL180M and 
rtT184G+rtS202I+rtM204V+rtL180M.13 That is, in patients with 
pre-existing LAM-resistance mutations, there is a higher rate of 
developing ETV resistance, which was found to be 39% after 4 
years.14
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So far, there are not enough data on how many viral qua-
sispecies and pre-existing drug resistance mutations exist in 
preantiviral therapy. Thus, the aim of this study is to investigate 
viral quasispecies in the polymerase gene of HBV and the pres-
ence of drug resistance mutations before and at initiation of 
antiviral treatment.
MATERIALS AND METHODS
1. Subjects
Six CHB patients with LAM failure were enrolled in this 
study. Patient sera were obtained at baseline (before treat-
ment), 6 months after treatment and at the time of virologic 
breakthrough (VB) during LAM treatment. VB was defined as 
an increase in the serum HBV DNA levels of ≥1 log10 copies/mL 
during treatment in patients with initially adequate viral sup-
pression.15 For the comparison of baseline quasispecies, we also 
used stored sera of six patients with HBeAg-positive CHB who 
showed HBeAg seroconversion and undetectable HBV DNA 
for more than 72 weeks during LAM therapy. Cirrhosis was 
clinically diagnosed with ultrasonographic evidence of surface 
nodularity, serum platelet count <100,000/mm3, and spleno-
megaly (>12 cm). Routine liver biochemical tests including 
aspartate aminotransferase, alanine aminotransferase, albumin, 
total bilirubin, prothrombin, and creatinine were performed us-
ing a sequential multiple autoanalyzer. HBeAg and antibodies 
to HBeAg were tested with enzyme-linked immunoassays (Dade 
Behring, Marburg, Germany). HBV DNA levels were quantified 
by polymerase chain reaction (PCR), using the COBAS TaqMan 
48 analyzer (Roche Molecular Systems Inc., Branchburg, NJ, 
USA) with a lower detection limit of 300 copies/mL. HBV geno-
typing was performed using line probe genotyping assay (INNO-
LiPA HBV Genotyping assay; Innogenetics, Ghent, Belgium).
2. Cloning and sequencing
DNA extraction was carried out with QIAamp DNA Mini Kit 
(Qiagen Inc., Hilden, Germany) following the manufacturer’s 
instructions. The primers were designed to the RT region of 
the HBV polymerase gene: forward 5’-GGTCACCATATTCTT-
GGGAA-3’, reverse 5’-GTGGGGGTTGCGTCAGCAAA-3’. PCR 
reactions were performed in 50 mL reaction volumes. The reac-
tion contained 10 mL of DNA extract, 1 mL of each primer (10 
mmoL), 0.2 mL of Taq polymerase high fidelity (5 U/mL), 5 mL 
of 10×Taq buffer, 2 mL of dNTP mixture, and 36.8 mL H2O. The 
PCR programs used were as follows: denaturing at 94oC for 5 
minutes, followed by 40 cycles of denaturing at 94oC 40 sec-
onds, annealing at 52oC for 1 minute and elongation at 72oC for 
1 minute and then a final extension at 72oC for 10 minutes.
PCR amplified HBV DNA was cloned into pGEM T Easy Vec-
tor (Promega Co., Madison, WI, USA) according to the manu-
facturer’s instructions. After transformation, 100 clones with the 
HBV insert were picked up at each time point. The colonies were 
grown overnight at 37oC in 3 mL Luria-Bertani broth mixed 
with ampicillin (100 mg/mL). Recombinant plasmid DNA was 
purified using the Wizard Plus SV Minipreps DNA Purification 
System (Promega Co.) following the manufacturer’s instruc-
tions. Purified plasmids were electrophoresed after digestion 
with restriction enzymes Xba I and Pst I (New England BioLabs, 
Beverly, MA, USA) and sequenced using primers, SP6 (5’-ATT 
TAG GTG ACA CTA TAG-3’) or T7 (5’-TAA TAC GAC TCA CTA 
TAG GG-3’). The reference gene of HBV genotype C was NCBI 
GenBank No. AF286594, which was considered the wild type.
RESULTS
1. Clinical characteristics and clone sequencing of HBV
All six patients with LAM failure had chronic infection by 
HBV of genotype C. There were four males and two females 
with a mean age of 54±12.5 years. Three of the patients had 
clinical evidence of cirrhosis. The mean duration of LAM 
therapy was 30.5±10.7 months, and the mean time to VB was 
27.8±11.3 months. ETV 1 mg had been administered for 2nd-
Table 1. Characteristics of the Patients
Variable
Patient with LAM failure Patient with response to LAM
1 2 3 4 5 6 7 8 9 10 11 12
Age/gender 56/M 48/M 51/M 43/M 48/F 78/F 42 56 39 58 39 42
HBV genotype C C C C C C C C C C C C
HBV DNA, IU/mL 4×104 2×105 6×104 8×108 8×107 6×105 3×106 3×105 7×107 2×104 5×106 5×104
HBeAg/anti-HBe (-/+) (-/+) (-/+) (+/-) (+/-) (+/-) (+-) (+/-) (+/-) (+/-) (+/-) (+/-)
Cirrhosis Yes No Yes No No Yes No No No Yes No Yes
Time to seroconversion, mo - - - - - - 26 19 14 24 30 23
Duration of LAM, mo 25 48 19 31 23 37 41 43 34 45 48 65
Time to VB, mo 22 48 15 28 23 31 - - - - - -
2nd line drug ETV ADV ADV ETV ADV ADV - - - - - -
LAM, lamivudine; M, male; F, female; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; anti-HBe, antibodies to HBeAg; VB, virologic break-
through; ETV, entecavir 1 mg; ADV, adefovir.
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line therapy in patient 1 and 4, and adefovir (ADV) 10 mg was 
started in the remaining patients (Table 1). Six patients (three 
males, mean age of 46±8.6 years) who responded to LAM thera-
py also had genotype C, and HBeAg seroconversion occurred at 
a mean of 22.5±5.6 months.
In order to determine the composition and changes of HBV 
quasispecies before and during LAM treatment in the patients 
with LAM failure, clone sequencing was performed at the 
baseline (prior to LAM therapy), at 6 months, and at VB. Fig. 1 
shows examples of the viral quasispecies in HBV P genes of pa-
tient 1 to 3 before treatment. In patient 1, 23 of 100 clones (23%) 
contained T38A+H55A, which was followed by T38A (21%), 
and E271Q (20%). The predominant HBV quasispecies in patient 
2 was R242A (36%), and the remaining were N76D+D134E 
(20%), D134E+R242A (17%), and D134E (13%).
In patient 3, there were a total of 81 quasispecies with various 
amino acid substitutions in H55, V191, and K333, which were 
almost equally distributed in 100 clones. The frequency of wild 
type HBV was 11% in patient 2. However, there was no wild 
type virus in patient 1 and 3.
2.	Pre-existing	antiviral	drug-resistant	mutations
Pretreatment viral quasispecies was compared among patients 
with LAM failure and those who responded to LAM therapy. 
Among six patients with LAM failure, cloning and sequencing 
data on the RT region of HBV revealed that LAM resistance mu-
tation, L180M or M204V/I substitutions, pre-existed in patient 
1, 2, 5, and 6, albeit a small percentage (1% to 2%). Moreover, 
1% of the clones in patient 1 and 4 harbored ADV resistance 
mutations, A181V. Whereas, only M204V/I substitution was 
identified in 1% of the clones in one patient who responded to 
LAM therapy. Neither L180M nor A181V mutation was detected 
in the six responders (Table 2).
3. Evolution of drug-resistant mutations
Table 3 shows the dynamic changes and proportions of qua-
sispecies in HBV P gene of six patients with LAM failure during 
treatment. At baseline, some colonies contained LAM or ETV re-
sistant mutations such as L80V/I, L180M, M204V/I, A181V, and 
N236H. In patient 1, 3, and 4, I169L substitution was also de-
tected. Interestingly, the colonies of patient 3 contained S202G, 
which is known as ETV signature resistance, in conjunction with 
I169L. At 6 months of LAM therapy, quasispecies variants bear-
ing LAM resistance mutations, M204V/I+L180M, appeared in 
all six patients. In patient 3 and 4, ADV related changes, N236H 
and A181T, became undetectable at this time point. In patient 1, 
ADV-associated variant N236H newly emerged in conjunction 
with M204I substitution. While ETV-related mutations became 
undetectable in patient 1, 3, and 4, I169L+L180M+M204V was 
detected in patient 6. At VB, ADV resistance mutations were not 
detected in any patient.
4.	Concomitant	overlapping	S	gene	changes
All patients showed at least one kind of concomitant en-
velope gene change, which overlaps the polymerase gene. In 
patient 1, changes of the P gene, rtW153Q, rtI169L, rtV173L, 
rtA181V, and rtM204V, corresponded to change of the S gene, 
rtG145R, rtF161H, rtE164D, and rtI195M, respectively (Table 
4). In patient 2, rtW153Q and rtW196L change, a termination 
codon caused by rtM204, was detected. The ADV resistance mu-
tation, rtA181V resulted in a concomitant change of rtL173F in 
patient 4.
DISCUSSION
In the present study, the HBV quasispecies of polymerase 
Fig. 1. Viral quasispecies in the hepatitis B virus (HBV) P genes of 
three patients. The identified number of quasispecies of each patient 
were 58, 31, and 81, respectively. The frequency of wild-type HBV 
was 11% in patient 2. However, there was no wild-type virus in pa-
tients 1 and 3. WT, wild-type (reference sequence): NCBI GeneBank 
no. AF286594 (HBV Pol_genotype C).
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RT domain in six patients with LAM resistance were examined 
before antiviral therapy, at 6 months of LAM therapy, and at 
VB. In addition, pretreatment sera were also analyzed for the 
viral quasispecies in six patients who had a good response to 
LAM therapy. The finding that more diverse HBV quasispecies 
was identified in LAM-failure patients than in LAM-responding 
patients and that the frequency of pre-existing M204V/I sub-
stitution was not different between two groups suggests that 
degree of overall viral quasispecies rather than M204V/I sub-
stitition might predict response to LAM. Sequence analysis of 
100 HBV clones isolated from sera of each patient with LAM 
failure at each time point revealed the evolution of the viral 
Table 2. Frequency of Pre-Existing Drug-Resistant Mutations According to Response to Lamivudine (LAM)
L80V/I V84I T128N W153Q I169L V173L L180M A181V M204V/I S202G Q215S N236H Overall
LAM failure
Patient 1 7 8 2 1 1 19
Patient 2 1 1 1 3
Patient 3 5 1 2 7 15
Patient 4 1 1 2 1 1 6
Patient 5 1/2 1 4
Patient 6 1 1 1 3
Responding to LAM
Patient 7 2 2
Patient 8 1 1 2
Patient 9 1 1
Patient 10 1 1
Patient 11 1 1
Patient 12 2 2
Data are presented as percentage.
Table 3. Evolution of Antiviral Drug-Resistant Mutations
Patient
Pretreatment (%) At 6 mo (%) At virologic breakthrough (%)
LAM ADV ETV LAM ADV ETV LAM ADV ETV
1 V173L (2)
L180M (1)
W153Q (7)
A181V (1) I169L (8) M204V/I (23/33)
L180M+ M204I (2)
L80I+204I (11)
M181L (1)
N236H (2)
M204I+N236H (1)
M204I (54)
L180M+M204I (2)
L180M+M204V (2)
L80I+M204I (44)
2 L180M (1)
L80V (1)
W153Q (1)
M204I/V (35/6)
L180M+M204V/I 
(53/2)
L180M+M204V 
(100)
3 V84I (5)
N236H (7)
I169L (1)
S202G (2)
M204I (91)
L180M+M204V/I 
(3/3)
M204I (19)
L180M+M204V 
(35)
L80M+M204V (46)
4 V173L (2) A181T (1) I169L (1)
Q215S (1)
M204V/I (4/84)
L180M+M204V/I 
(7/4)
M204V/I (2/57)
L180M+M204V 
(26)
5 M204V/I (1/2) Q215S (1) L180M (2)
M204V/I (2/32)
L180M+M204V 
(64)
M204V/I (7/21)
L180M+M204V/I 
(42/28)
6 L80I (1)
V173L (1)
L180M (1)
M204I (40)
L180M+M204V 
(4/2)
L80M+M204I (54)
I169L+L180M 
+M204 (2)
L180M+M204V 
(7/2)
L80I +M204I (65)
I169L+L180M 
+M204V (52)
LAM, lamivudine; AVD, adefovir; ETV, entecavir.
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quasispecies. Although LAM is no longer recommend as a first-
line therapy for CHB due to high incidence of drug resistance,15 
many patients especially in Asian countries have been exposed 
to this drug. Hence, analysis of substitutions in the sequence of 
the polymerase gene of this error-prone HBV would be required 
to select the rescue agent for patients with LAM resistance.16 
Furthermore, it was reported that substitutions at rtI184, rtS202, 
and/or rtM250 were already detected in LAM-refractory sub-
jects at baseline ETV treatment.10 As seen in Fig. 1, many viral 
quasispecies of HBV polymerase gene existed even before LAM 
therapy. Pre-existing LAM-resistance mutation, rtM204V/I, was 
found in 3% (3/100) of clones in patient 5, whereas rtL180M 
mutation was detected in 1% (1/100) of clones in patient 1 and 
2. LAM compensatory mutations, rtL80V/I and/or rtV173L, were 
seen in patient 1, 2, 4, and 6. Our result is in agreement with 
a previous report that some viral populations harbor YMDD 
mutants in LAM-untreated asymptomatic hepatitis B carriers.17 
Emergence of ETV resistance seems to be infrequent, in particu-
lar in treatment-naïve patients. The importance of pre-existing 
ETV resistant HBV variants was highlighted in a previous study, 
in which three out of 111 (2.7%) patients had substitutions in 
the HBV polymerase gene corresponding to variants associated 
with ETV resistance (rtS202S/I) prior to LAM treatment.18 In 
another large-scale study, three out of 255 (1.2%) treatment-
naïve patients had the rtM250L/V mutation typical of ETV resis-
tance.19 In our sequencing data, rtI169L mutation was present in 
8%, 1%, and 1% of 100 colonies in patient 1, 3, and 4, as well 
as rtA181V/T ADV resistance mutations in patient 1 and 4. The 
significance and clinical relevance of these pre-existing ETV 
or ADV resistance variants of minor fractions remains to be 
elucidated by a large number of patients and long term follow-
up. Nevertheless, the selective pressure of nucleos(t)ide analogue 
therapy will enable the pre-existing mutants to generate a prog-
eny virus that is more fit and can spread more rapidly in the 
liver.
As expected, while rtL180M and rtM204V/I variants were 
present as a single mutation prior to LAM treatment, the 
rtL180M+rtM204V/I combination mutations became predomi-
nant at 6 months and at VB. Interestingly, the rtV173A/L muta-
tion that had been described in previous reports20,21 was detected 
at baseline, but not thereafter in patient 1, 4, and 6. Regarding 
HBV quasispecies associated with ADV resistance, the rtV84I/
S, rt N236H, rtA181T, and rtQ215H mutations, were detected at 
baseline and at 6 months of LAM therapy in patient 1, 3, 4, and 
6. However, no colony harboring such variants was observed 
at VB. In addition to classical ADV resistance mutations such 
as rtN236S or rtA181T, a few other related-variants including 
rtV84I/S, rtL84S, and rtQ215H were identified before VB in 
patient 1, 3, 4, and 6. It is known that, for nucleos(t)de-naive 
individuals treated with ETV, LAM resistant quasispecies are 
necessary prior to emergence of ETV resistance variants. This, 
so-called two-hit model was suggested for the development of 
ETV resistance in that LAM resistance mutations were selected 
initially and one or two additional ETV resistance mutations 
were acquired in the same virus afterwards.12,20,22 Guo et al.23 
cloned and sequenced the HBV RT of a patient who had been 
treated with ETV 0.5 mg as a first line therapy developing ETV 
resistance. The LAM resistance quasispecies (rtM204V±rt180M) 
emerged as early as 48 weeks, and ETV resistant quasispecies 
(rtM204±rtL180M plus S202G) were found after 112 weeks.23 
Unlike the previous study, rtI169S/L and/or rtS202G mutations 
were detected in the absence of LAM resistance variants at pre-
treatment, even though those variants disappeared during LAM 
therapy until VB. This finding suggests that some viral popula-
tion might harbor ETV resistance mutations, without preceding 
LAM resistance variants in treatment-naïve patients who receive 
ETV 0.5 mg. Although we demonstrated viral diversity even at 
pretreatment by cloning and sequencing, it needs to be kept in 
mind that most of viral quasispecies shown in Fig. 1 have no 
clinical implication because we did not perform any susceptibil-
ity test for those variants.
The polymerase gene overlaps the envelope gene and thus 
mutations selected during antiviral resistance can cause con-
comitant changes to the overlapping reading frame with the 
major resistance mutations for LAM, ADV, and ETV.16 We found 
that HBsAg changes corresponding to resistance mutations 
existed even at pretreatment. For instance, a change at sI195M, 
sW196L associated with rtM204V/I was detected in one and two 
of 100 colonies in patient 1 and 5, respectively. The mutation at 
sF161H, which is located adjacent to the region that was defined 
as the “a” determinant, in association with rtI169L mutation 
was observed in patient 1, 3, and 4. The clinical implication of 
these reciprocal changes of the P and S genes is that they might 
affect diagnostic assays, vaccine escape, replication fitness, and 
pathogenicity of HBV.
In conclusion, we found that various HBV quasispecies as-
sociated with drug resistance existed as well as S gene variants 
before treatment and the quasispecies dynamically changed 
along with LAM therapy.
Table	4. Reciprocal Changes of P and S Genes at Pretreatment
Location  
in P gene
Location  
in S gene
Patient
1 2 3 4 5 6
W153Q
I169L
V173L
A181V
T184L
M204V
M204I
Q215S
sG145R
sF161H
sE164D
sL173F
sL175F
sI195M
sW196L
sS207R
7
8
2
1
1
1
1
1
2
1
1
1
2
1
Data are presented as percentage.
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